Brief: Mbx Biosciences Completes Enrollment In Phase 2 Avail Trial Of Mbx 2109 (Canvuparatide) For Hypoparathyroidism
03/03/2025 14:17
March 3 (Reuters) - MBX Biosciences Inc MBX.O: MBX BIOSCIENCES COMPLETES ENROLLMENT IN PHASE 2 AVAIL™ TRIAL OF MBX 2109 (CANVUPARATIDE) FOR HYPOPARATHYROIDISM Source text: ID:nGNX3YfccH Further company coverage: MBX.O (Reuters.Briefs@thomsonreuters.com)
Recent news on MBX Biosciences
See all newsU.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC Solutions
MBX Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: MBX Biosciences Announces Executive Leadership Transition To Support The Company’S Next Phase Of Growth
MBX Biosciences falls after executive shakeup
U.S. STOCKS ON THE MOVE-SpaceX, Tesla, Woodside Energy Group